Real-World Effectiveness and Safety of Pre-mix 70/30 Insulin Initiation in Poorly Controlled Type 2 Diabetes: a Multicentre Pakistani Cohort

INTRODUCTION: In lower- and middle-income countries, insulin choice at initiation is driven as much by cost as by clinical need. Low-cost human pre-mix 70/30 insulin predominates in Pakistan, yet prospective real-world evidence on its outcomes and true cost is scarce. METHODS: In this investigator-initiated, single-arm, prospective observational study at 12 sites in Pakistan, insulin-naïve adults with type 2 diabetes and HbA1c 9% or higher despite two or more oral drugs were started on human pre-mix 70/30 insulin at physician discretion and followed for 6 months, with assessments at baseline, day 90 and day 180. The primary outcomes were change in HbA1c and incidence of hypoglycaemia (classified by American Diabetes Association levels). A descriptive cost-consequence analysis (patient out-of-pocket perspective) was a pre-specified secondary exploratory objective. RESULTS: A total of 384 of 430 screened patients were enrolled, with a mean baseline HbA1c of 11.2 ± 1.5%. HbA1c fell to 9.3 ± 1.5% at day 90 and to 8.8 ± 1.5% at day 180, a mean reduction of 2.3 ± 1.8% (p < 0.001), with no significant change in body weight. By day 180, 242 of 310 patients (78.1%) had achieved at least a 1% reduction in HbA1c, and 28 patients (9.0%) reached below 7%. Confirmed hypoglycaemia below 70 mg/dL occurred in eight patients (2.1%), and no severe or treatment-limiting events were recorded. Mean 6-month direct medical cost was 36,269 Pakistani Rupee (PKR) per patient. Insulin acquisition accounted for just PKR 7200 of this (19.8%), while consultations, injection consumables, diagnostics and self-monitoring made up the remainder. CONCLUSIONS: In routine practice, human pre-mix 70/30 insulin produced clinically meaningful and sustained HbA1c reductions with a favourable safety profile, supporting its effectiveness for insulin initiation in poorly controlled type 2 diabetes. Affordability, however, was governed by the total cost of care rather than insulin price alone.

Authors

Institutions

Publication Details

Journal
Diabetes Therapy
Published
2026-11-18
DOI
https://doi.org/10.1007/s13300-026-01939-4
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-World Effectiveness and Safety of Pre-mix 70/30 Insulin Initiation in Poorly Controlled Type 2 Diabetes: a Multicentre Pakistani Cohort

Riasat Ali Khan, Gohar Ali Khan, Syed Abbas Raza, Mazhar Faiz Alam et al.
Diabetes Therapy
Diabetes Treatment and Management
article

Real-World Effectiveness and Safety of Pre-mix 70/30 Insulin Initiation in Poorly Controlled Type 2 Diabetes: a Multicentre Pakistani Cohort

Riasat Ali Khan, Gohar Ali Khan, Syed Abbas Raza, Mazhar Faiz Alam, Amena Moazzam Baig, Uneeba Syed, Ibrar Ahmad, Azizul Hasan Aamir, Saeed Ahmed Mahar, Faisal Masood Qureshi, Hafiz Farhan Rashid, Mohammad Imtiaz Hassan
article en

Abstract

INTRODUCTION: In lower- and middle-income countries, insulin choice at initiation is driven as much by cost as by clinical need. Low-cost human pre-mix 70/30 insulin predominates in Pakistan, yet prospective real-world evidence on its outcomes and true cost is scarce. METHODS: In this investigator-initiated, single-arm, prospective observational study at 12 sites in Pakistan, insulin-naïve adults with type 2 diabetes and HbA1c 9% or higher despite two or more oral drugs were started on human pre-mix 70/30 insulin at physician discretion and followed for 6 months, with assessments at baseline, day 90 and day 180. The primary outcomes were change in HbA1c and incidence of hypoglycaemia (classified by American Diabetes Association levels). A descriptive cost-consequence analysis (patient out-of-pocket perspective) was a pre-specified secondary exploratory objective. RESULTS: A total of 384 of 430 screened patients were enrolled, with a mean baseline HbA1c of 11.2 ± 1.5%. HbA1c fell to 9.3 ± 1.5% at day 90 and to 8.8 ± 1.5% at day 180, a mean reduction of 2.3 ± 1.8% (p < 0.001), with no significant change in body weight. By day 180, 242 of 310 patients (78.1%) had achieved at least a 1% reduction in HbA1c, and 28 patients (9.0%) reached below 7%. Confirmed hypoglycaemia below 70 mg/dL occurred in eight patients (2.1%), and no severe or treatment-limiting events were recorded. Mean 6-month direct medical cost was 36,269 Pakistani Rupee (PKR) per patient. Insulin acquisition accounted for just PKR 7200 of this (19.8%), while consultations, injection consumables, diagnostics and self-monitoring made up the remainder. CONCLUSIONS: In routine practice, human pre-mix 70/30 insulin produced clinically meaningful and sustained HbA1c reductions with a favourable safety profile, supporting its effectiveness for insulin initiation in poorly controlled type 2 diabetes. Affordability, however, was governed by the total cost of care rather than insulin price alone.

Diabetes Therapy
Punjab Institute of Cardiology (PK), Allama Iqbal Medical College (PK), Lady Reading Hospital (PK), Indus Hospital (PK), Bahawal Victoria Hospital (PK), Northwest General Hospital and Research Center (PK), Shaukat Khanum Memorial Cancer Hospital and Research Center (PK), National Institute of Cardiovascular Diseases (PK), National Hospital and Medical Center (PK)
Good health and well-being
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon